The five-year project, titled “Harnessing β-Catenin and NKG2D to Enable HLA-Independent CD8⁺ T-Cell Immunotherapy Against Acute Myeloid Leukemia,” runs through July 2031 and represents one of the most ambitious attempts yet to circumvent a central obstacle in leukemia immunology. At the heart of the problem lies a protein system called HLA class I, a molecular display platform found on the surface of nearly all cells in the body. HLA molecules present fragments of intracellular proteins to circulating CD8⁺ T cells, the cytotoxic “killer” lymphocytes of the adaptive immune system. When a cell becomes cancerous, it displays abnormal peptide fragments on its HLA molecules, effectively raising a flag that invites T-cell destruction. This HLA-dependent recognition is the foundation of most T-cell-based cancer immunotherapies, including engineered CAR T-cell approaches that have produced dramatic remissions in certain blood cancers.

Acute myeloid leukemia, however, has evolved a devastating countermeasure. AML cells can downregulate or completely lose expression of HLA class I molecules, rendering them effectively invisible to the cytotoxic T cells that would otherwise destroy them. This immune-evasion strategy is particularly insidious because it does not merely blunt the effect of natural immunity; it also undermines precisely engineered therapies built around HLA-dependent antigen recognition. For patients with high-risk or relapsed AML, the failure of immune recognition contributes directly to the disease’s grim prognosis, making AML one of the most lethal hematologic malignancies in adults.

Karimi’s laboratory has identified an alternative recognition pathway that may offer a way around this evasion mechanism. “Our research has identified another way that these immune cells may recognize leukemia cells without relying on HLA,” Karimi explained. “In this study, we aim to understand how the alternative pathway is regulated in immune cells from patients with AML and how this pathway could be strengthened to improve immune-based treatments for leukemia.” The pathway centers on NKG2D, an activating receptor expressed on natural killer cells and subsets of T cells, including CD8⁺ T cells. Unlike conventional T-cell receptors, NKG2D does not require HLA-mediated peptide presentation. Instead, it recognizes stress-induced ligands that frequently appear on the surface of transformed or infected cells. By exploiting this HLA-independent axis, Karimi’s team hopes to engineer or enhance CD8⁺ T cells capable of detecting and eliminating AML cells even when those cells have shed their HLA molecules.

The role of β-catenin in this system adds another layer of scientific intrigue. β-catenin is a central signaling molecule in the Wnt pathway, best known for its role in embryonic development and cell proliferation, but increasingly implicated in cancer biology and immune regulation. Aberrant β-catenin activity in tumor cells has been linked to immune suppression in the tumor microenvironment, and signaling events within T cells themselves can shape their function, persistence, and cytotoxic capacity. By mapping how β-catenin influences the NKG2D-dependent recognition pathway, Karimi’s project seeks to uncover the regulatory logic that determines whether this alternative immune recognition can be therapeutically amplified in real patients, whose immune cells may differ substantially from those studied in laboratory models.

The ambition of the project extends beyond simply finding leukemia cells. AML develops primarily in the bone marrow, an anatomical sanctuary where leukemia cells actively sculpt their surroundings into a self-protective niche. “AML develops mainly in the bone marrow, where leukemia cells can create an environment that helps them hide from the immune system and avoid being recognized by cancer-fighting immune cells,” Karimi noted. This immunosuppressive microenvironment can disable infiltrating T cells through metabolic exhaustion, inhibitory checkpoint signaling, and direct suppression by stromal and myeloid cells recruited to the leukemia’s service. Understanding these escape mechanisms in detail, Karimi argues, is the prerequisite for dismantling them. “We want to understand the mechanisms AML cells use to escape immune detection and weaken these modified immune cells,” he said. “By identifying these escape strategies, we hope to find ways to overcome them and improve the ability of immune cells to recognize and destroy AML. Ultimately, this knowledge could help us develop more effective HLA-independent immunotherapies for patients with AML.”

The clinical stakes of this work are illuminated by the current standard of care for patients whose AML returns after initial treatment or who present with high-risk disease features. For these individuals, physicians often turn to allogeneic stem cell transplantation, a procedure in which a patient’s blood-forming system is replaced with that of a healthy donor. The therapeutic power of transplantation comes not merely from the replacement of the marrow itself but from the donor’s immune cells, which can mount what oncologists call a graft-versus-leukemia effect. Donor T cells survey the recipient’s tissues, identify residual leukemia as foreign, and attack it, providing a potent and sometimes curative immunologic assault on the disease. “These donor immune cells can recognize and attack the leukemia, producing what is called a graft-versus-leukemia effect,” Karimi explained.

But this biological double-edged sword cuts in a terrible direction. The same donor immune cells that attack leukemia cannot always distinguish malignant tissue from the patient’s healthy organs, skin, liver, and gastrointestinal tract. The result is graft-versus-host disease, or GVHD, a potentially devastating complication in which the transplanted immune system turns against its new host. “However, the same donor immune cells can also attack the patient’s healthy tissues,” Karimi said. “This serious complication is called graft-versus-host disease, or GVHD.” The problem is compounded by a stark therapeutic vacuum: no approved treatments specifically for GVHD are available, and severe cases can be extraordinarily difficult to control, causing significant illness and death. For many patients and their physicians, the decision to pursue transplantation becomes a calculus of risk, weighing the curative potential of the graft-versus-leukemia effect against the danger of a runaway donor immune response.

This is precisely where Karimi’s HLA-independent strategy could prove transformative. If engineered CD8⁺ T cells can be tuned to recognize AML selectively through NKG2D-dependent mechanisms while remaining inert toward healthy tissue, the therapeutic ideal that allogeneic transplantation only approximates—maximal anti-leukemia activity with minimal collateral damage—could be realized directly. “Therefore, one of our major goals is to develop immune cells that can effectively attack AML while avoiding damage to healthy tissues,” Karimi said. “We will use this knowledge as a foundation to develop new immune-based therapies that can ultimately be translated directly to patients with AML.” The phrase “translated directly to patients” signals the translational orientation of the program: rather than remaining a purely mechanistic inquiry, the project is designed to generate actionable biological knowledge that can inform the design of cellular therapies testable in clinical settings.

The significance of the award extends beyond a single disease. HLA loss and downregulation are not unique to AML; numerous solid tumors and other hematologic malignancies employ similar strategies to escape T-cell surveillance. Immunotherapies that operate independently of HLA presentation could therefore offer a blueprint for treating cancers that have historically eluded the most successful immune-based approaches of the past decade. Moreover, understanding how β-catenin signaling regulates NKG2D-mediated recognition may reveal broader principles governing how innate-like immune recognition can be harnessed in engineered T cells, an area of intense interest across immuno-oncology.

For the roughly twenty thousand Americans diagnosed with AML each year, many of them older adults whose disease carries a five-year survival rate that remains tragically low, the research represents a beacon of rational, mechanistically grounded hope. The five-year funding window through July 2031 gives Karimi’s laboratory the sustained resources needed to move from molecular dissection to therapeutic concept, a timeline that reflects the complexity of the challenge and the National Cancer Institute’s confidence in the scientific foundation underlying it. As the field of cancer immunotherapy enters its second decade of mainstream clinical success, work like this points toward its next frontier: cancers that have learned to hide from the immune system’s primary surveillance system, and the scientists determined to give immune cells a second way to see them.

Cancer immunotherapy has transformed oncology by shifting part of the fight against tumors from conventional chemotherapy and radiation toward the patient’s own immune system. Among the most important advances are immune checkpoint inhibitors, which release molecular brakes that restrain T cells, and engineered or expanded T-cell therapies designed to target malignant cells. Yet these treatments remain ineffective for many patients. Some tumors lack the biological signals needed for T-cell recognition, while others create a hostile microenvironment that suppresses immune activity or evolve rapidly enough to escape attack.

T cells are specialized immune cells capable of identifying abnormal proteins displayed on the surface of cancer cells. After recognizing their targets, they form a close contact zone with the tumor cell, known as an immunological synapse, and release toxic molecules that can trigger the cancer cell to die. This process depends on a series of precisely coordinated interactions between the T cell and the tumor. If any part of that process is weakened—whether because the tumor hides its identifying markers, blocks immune signaling or resists cell death—the immune response may fail even when large numbers of T cells are present.

To search for ways to overcome these barriers, Puig-Saus’ laboratory has developed a drug screening platform capable of testing thousands of chemical compounds. Such platforms allow scientists to observe how individual molecules influence interactions between immune cells and cancer cells. Rather than examining only whether a drug kills tumor cells directly, the UCLA team can investigate whether a compound changes the biological relationship between the tumor and the immune system. This distinction is important because many promising immunotherapy-enhancing drugs may not be effective as standalone cancer treatments.

The screening effort has identified two leading candidates with complementary effects. One compound appears to strengthen the physical and functional interaction between T cells and cancer cells. By improving the formation or stability of the cellular contact needed for immune attack, the drug could help T cells deliver their destructive signals more effectively. This type of intervention may be especially valuable in tumors where immune cells reach the cancer but fail to establish a sufficiently strong or sustained response.

The second candidate acts primarily on tumor cells rather than directly modifying T cells. Preliminary findings suggest that it makes cancer cells more vulnerable to destruction by T cells. In technical terms, the drug may alter pathways controlling tumor-cell survival, stress responses or susceptibility to the molecular machinery released by activated immune cells. The compound could therefore increase the “killability” of cancer cells without requiring researchers to permanently reprogram or intensify the immune cells themselves, potentially offering a different route to improving treatment efficacy.

The new grant will support experiments in preclinical melanoma models to determine whether either compound can boost existing immunotherapies. Researchers will evaluate combinations with immune checkpoint inhibitors and T-cell-based treatments, measuring tumor growth, immune-cell activity, treatment durability and possible toxic effects. They will also study how the compounds work at the molecular level, seeking to identify the cellular pathways responsible for improved immune recognition or tumor destruction. Understanding those mechanisms will be essential for selecting appropriate patients and designing safe clinical trials.

Melanoma provides a particularly important testing ground because it can carry a high number of mutations, creating abnormal proteins that immune cells may recognize. Despite this vulnerability, melanoma can still suppress immune responses and develop resistance after an initial treatment benefit. A drug that restores the effectiveness of T cells or exposes a tumor’s hidden weaknesses could help extend responses in patients who do not benefit from current therapies or whose cancers return after treatment. The researchers will need to establish whether the compounds work broadly across genetically different melanomas or only in tumors with particular biological features.

“If successful, these drugs could significantly improve the effectiveness of current immunotherapies and help more patients benefit from these treatments,” Puig-Saus said. She is an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA. She is also a member of the UCLA Broad Stem Cell Research Center and the UCLA Parker Institute for Cancer Immunotherapy. Because the compounds are being developed as partners for existing treatments rather than replacements for them, the strategy could potentially be adapted to other cancers in which immune evasion and resistance limit therapeutic success.

The project remains at the preclinical stage, and its compounds have not yet been established as safe or effective treatments for people. Many candidates that show promise in laboratory systems ultimately fail because they produce unexpected toxicity, lose activity in complex tumors or cannot be delivered at useful doses. The UCLA team’s upcoming studies will therefore examine both therapeutic benefit and safety while tracing the precise mechanisms involved. If the candidates continue to perform well, they could provide a foundation for future clinical development and offer a new way to make the immune system’s attack on cancer more precise, persistent and effective.

Subject of Research: Cancer immunotherapy enhancement using drug-based strategies for melanoma and potentially other cancers

Article Title: UCLA Team Receives $3.9 Million Grant to Develop Drugs That Could Strengthen Cancer Immunotherapy

Web References: https://www.uclahealth.org/cancer/members/cristina-puig-saus; https://www.uclahealth.org/cancer

Keywords: Immunotherapy, cancer immunology, immune system, immune response, cancer research, cancer, melanoma, skin cancer, T-cell therapy, immune checkpoint inhibitors

Each year, over 80,000 individuals aged between 15 and 39 receive a cancer diagnosis, and currently, more than two million young cancer survivors reside in the United States alone. This demographic faces a complex constellation of issues as they transition from treatment to survivorship. Unlike pediatric or older adult cancer patients, AYAs confront a distinct set of psychosocial and physiological stressors, including the interruption of critical life milestones such as educational advancement, career initiation, and family planning. Their post-treatment landscape is shaped both by the biological repercussions of the disease and its treatment, and by the broader societal ramifications of their experience.

Leading this ambitious endeavor is Dr. Shoshana Rosenberg, an associate professor of population health sciences at Weill Cornell Medicine. Dr. Rosenberg emphasizes the pressing need to understand the particular needs of young survivors, which diverge substantially from those of other age groups. The study seeks to garner direct insights from patients to inform and refine clinical care delivery. By focusing on patient-reported experiences and real-world outcomes, the research aims to translate these findings into more empathetic and effective healthcare strategies tailored for the AYA population.

Central to the study’s methodology is the creation of a meticulously assembled cohort of 2,000 adolescent and young adult cancer survivors located in New York City. This diverse cohort will be monitored longitudinally to evaluate both immediate and delayed consequences of novel therapeutic approaches, including biological agents and immunotherapies now increasingly prominent in oncology. Unlike traditional chemotherapy and radiation, these newer treatments have complex profiles regarding long-term toxicity and survivorship outcomes. Documenting these effects will provide critical data to delineate survivorship patterns unique to modern treatment paradigms.

One distinctive aspect of this research is its comprehensive approach to the myriad challenges AYAs face post-treatment. The study places considerable emphasis on sensitive yet consequential issues such as fertility preservation and sexual health, acknowledging that cancer and its treatments can profoundly impact reproductive potential and intimacy. In tandem, the financial burdens incurred by young survivors are also scrutinized, recognizing that the economic strain of cancer care can exacerbate psychological distress and hinder access to follow-up services. By addressing these interconnected domains, the research fosters a holistic understanding of survivorship.

The project deploys an innovative mobile application designed expressly for this digitally adept generation to facilitate seamless communication between researchers and participants. This app will enable survivors to regularly complete surveys and provide health updates over the study period. Moreover, it is equipped to collect sensor-derived data related to physical activity and sleep patterns, delivering an unprecedented window into daily functioning and overall well-being through passive monitoring. This multi-modal data collection promises to enrich the characterization of health trajectories following cancer treatment.

Beyond patient self-report and passive sensor data, the study integrates biological sample collection and access to electronic medical records (EMRs). Leveraging EMRs allows for real-time clinical data assimilation, including lab results and treatment history, strengthening the robustness of longitudinal analyses. Biological samples may aid in identifying biomarkers predictive of late-onset complications, offering the tantalizing possibility of preemptive interventions. Such integrative data strategies exemplify the movement toward precision medicine in oncology survivorship, aiming to tailor supportive care based on individual risk profiles.

An equally important goal of the project is to translate findings into actionable interventions that can preempt or mitigate adverse long-term health outcomes. By identifying risk factors for sequelae such as cardiotoxicity, secondary malignancies, or psychological distress, the research hopes to enable earlier clinical interventions. Furthermore, the study seeks to dismantle barriers of accessibility to supportive care services, enhancing equity in survivorship care for AYAs from diverse socioeconomic and cultural backgrounds. The intention is to promote not only survival but quality of life and functional recovery.

The mobile platform also holds potential beyond data collection—serving as a conduit for disseminating supportive care resources and fostering a sense of community among participants. Social isolation is a common and often overlooked plight for young survivors, and digital connectivity can offer critical psychosocial support. By creating virtual spaces for peer engagement and information exchange, the study envisions reinforcement of resilience and empowerment. This approach aligns with emerging trends in digital health interventions aimed at chronic disease management and mental health support.

Dr. Rosenberg expresses hope that this pioneering research will illuminate previously unanswered questions surrounding the AYA cancer survivor experience. The study is poised to inform communication strategies between healthcare providers and patients, ensuring that the unique concerns of young survivors are acknowledged and addressed effectively throughout the continuum of care. Improving dialogue and understanding within clinical encounters is fundamental to fostering shared decision-making and personalized survivorship planning.

Joining Dr. Rosenberg are co-principal investigators Dr. Danielle Friedman, an attending physician at Memorial Sloan Kettering Cancer Center, and Dr. Jeanine Genkinger, an associate professor of epidemiology at Columbia University Mailman School of Public Health. Their combined expertise in clinical oncology, epidemiology, and population health sciences bolsters the interdisciplinary nature of this comprehensive research initiative. Together, the team aims to bridge gaps between clinical research and practical support mechanisms for AYAs battling the sequelae of cancer and its treatment.

This study reflects a broader paradigm shift in oncology, moving from a sole focus on disease eradication toward a more nuanced understanding of survivorship and quality of life. By harnessing cutting-edge technology and cross-disciplinary collaboration, the project exemplifies future directions for cancer research and care delivery. The integration of patient engagement, digital health tools, biomarker discovery, and social determinants of health marks an important evolution in addressing the needs of historically overlooked populations.

Ultimately, the funding and research efforts spearheaded by Weill Cornell Medicine and collaborators aspire to create a replicable model for AYA cancer survivorship care. Insights garnered from this New York City cohort could catalyze policy changes, guide healthcare infrastructure development, and inspire similar studies nationally and globally. As survival rates improve across cancer types, the imperative to optimize long-term outcomes and holistic well-being for young survivors stands as a defining challenge—and opportunity—of modern oncology.

Subject of Research: Adolescent and Young Adult (AYA) Cancer Survivorship and Supportive Care Development

Article Title: Innovative Research Unveils the Hidden Struggles of Young Cancer Survivors: A Five-Year Study at Weill Cornell Medicine

News Publication Date: Not specified

Web References:

• Dr. Shoshana Rosenberg’s Faculty Profile, Weill Cornell
• Dr. Danielle Friedman, Memorial Sloan Kettering Cancer Center
• Dr. Jeanine Genkinger, Columbia University Mailman School of Public Health

Image Credits: Weill Cornell Medicine

Keywords: Cancer, Adolescent and Young Adult Survivors, Cancer Survivorship, Immunotherapy, Biological Treatments, Long-term Effects, Fertility Concerns, Financial Stress, Digital Health, Mobile Applications, Biomarkers, Supportive Care, Patient-Centered Research